202 related articles for article (PubMed ID: 36230969)
1. Hypoxia-Inducible Expression of Annexin A6 Enhances the Resistance of Triple-Negative Breast Cancer Cells to EGFR and AR Antagonists.
Williams SD; Smith TM; Stewart LV; Sakwe AM
Cells; 2022 Sep; 11(19):. PubMed ID: 36230969
[TBL] [Abstract][Full Text] [Related]
2. Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer.
Li T; Tao Z; Zhu Y; Liu X; Wang L; Du Y; Cao J; Wang B; Zhang J; Hu X
Cell Death Dis; 2021 Jul; 12(7):684. PubMed ID: 34238922
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors.
Widatalla SE; Korolkova OY; Whalen DS; Goodwin JS; Williams KP; Ochieng J; Sakwe AM
Carcinogenesis; 2019 Aug; 40(8):998-1009. PubMed ID: 30590459
[TBL] [Abstract][Full Text] [Related]
4. Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors.
Koumangoye RB; Nangami GN; Thompson PD; Agboto VK; Ochieng J; Sakwe AM
Mol Cancer; 2013 Dec; 12(1):167. PubMed ID: 24354805
[TBL] [Abstract][Full Text] [Related]
5. Diverse Roles of Annexin A6 in Triple-Negative Breast Cancer Diagnosis, Prognosis and EGFR-Targeted Therapies.
Korolkova OY; Widatalla SE; Williams SD; Whalen DS; Beasley HK; Ochieng J; Grewal T; Sakwe AM
Cells; 2020 Aug; 9(8):. PubMed ID: 32784650
[TBL] [Abstract][Full Text] [Related]
6. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
El Guerrab A; Zegrour R; Nemlin CC; Vigier F; Cayre A; Penault-Llorca F; Rossignol F; Bignon YJ
PLoS One; 2011; 6(9):e25080. PubMed ID: 21966417
[TBL] [Abstract][Full Text] [Related]
7. Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility.
Whalen DS; Widatalla SE; Korolkova OY; Nangami GS; Beasley HK; Williams SD; Virgous C; Lehmann BD; Ochieng J; Sakwe AM
Oncotarget; 2019 Jan; 10(2):133-151. PubMed ID: 30719209
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets.
Korolkova OY; Widatalla SE; Whalen DS; Nangami GN; Abimbola A; Williams SD; Beasley HK; Reisenbichler E; Washington MK; Ochieng J; Mayer IA; Lehmann BD; Sakwe AM
PLoS One; 2020; 15(4):e0231711. PubMed ID: 32298357
[TBL] [Abstract][Full Text] [Related]
9. Reduced Expression of Annexin A6 Induces Metabolic Reprogramming That Favors Rapid Fatty Acid Oxidation in Triple-Negative Breast Cancer Cells.
Williams SD; Sakwe AM
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267416
[TBL] [Abstract][Full Text] [Related]
10. Annexin A6 improves anti-migratory and anti-invasive properties of tyrosine kinase inhibitors in EGFR overexpressing human squamous epithelial cells.
Hoque M; Elmaghrabi YA; Köse M; Beevi SS; Jose J; Meneses-Salas E; Blanco-Muñoz P; Conway JRW; Swarbrick A; Timpson P; Tebar F; Enrich C; Rentero C; Grewal T
FEBS J; 2020 Jul; 287(14):2961-2978. PubMed ID: 31869496
[TBL] [Abstract][Full Text] [Related]
11. SUMOylation of AnxA6 facilitates EGFR-PKCα complex formation to suppress epithelial cancer growth.
Sheng Z; Cao X; Deng YN; Zhao X; Liang S
Cell Commun Signal; 2023 Aug; 21(1):189. PubMed ID: 37528485
[TBL] [Abstract][Full Text] [Related]
12. Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer.
Jinna N; Rida P; Smart M; LaBarge M; Jovanovic-Talisman T; Natarajan R; Seewaldt V
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012111
[TBL] [Abstract][Full Text] [Related]
13. Annexin A6 inhibits Ras signalling in breast cancer cells.
Vilá de Muga S; Timpson P; Cubells L; Evans R; Hayes TE; Rentero C; Hegemann A; Reverter M; Leschner J; Pol A; Tebar F; Daly RJ; Enrich C; Grewal T
Oncogene; 2009 Jan; 28(3):363-77. PubMed ID: 18850003
[TBL] [Abstract][Full Text] [Related]
14. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
[TBL] [Abstract][Full Text] [Related]
15. Annexin A6 is a scaffold for PKCα to promote EGFR inactivation.
Koese M; Rentero C; Kota BP; Hoque M; Cairns R; Wood P; Vilà de Muga S; Reverter M; Alvarez-Guaita A; Monastyrskaya K; Hughes WE; Swarbrick A; Tebar F; Daly RJ; Enrich C; Grewal T
Oncogene; 2013 Jun; 32(23):2858-72. PubMed ID: 22797061
[TBL] [Abstract][Full Text] [Related]
16. Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation.
Shome R; Ghosh SS
Cell Oncol (Dordr); 2021 Apr; 44(2):405-422. PubMed ID: 33398673
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.
Wang X; Petrossian K; Huang MJ; Saeki K; Kanaya N; Chang G; Somlo G; Chen S
J Steroid Biochem Mol Biol; 2021 Feb; 206():105791. PubMed ID: 33271252
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress.
Jabbarzadeh Kaboli P; Luo S; Chen Y; Jomhori M; Imani S; Xiang S; Wu Z; Li M; Shen J; Zhao Y; Wu X; Hin Cho C; Xiao Z
Gene; 2022 Mar; 816():146171. PubMed ID: 35026293
[TBL] [Abstract][Full Text] [Related]
19. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.
Cuenca-López MD; Montero JC; Morales JC; Prat A; Pandiella A; Ocana A
BMC Cancer; 2014 Apr; 14():302. PubMed ID: 24779793
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
